**Core Concept**
The treatment for genotype 1a of hepatitis C involves direct-acting antivirals (DAAs) that target specific viral proteins, leading to sustained virological response (SVR) and improved liver function.

**Why the Correct Answer is Right**
The treatment of genotype 1a hepatitis C typically involves a combination of two or three DAAs, including a protease inhibitor (e.g., grazoprevir or simeprevir), a non-nucleoside inhibitor (e.g., elbasvir), and a nucleotide inhibitor (e.g., sofosbuvir). This combination targets the NS3/4A protease, NS5A protein, and NS5B polymerase, respectively, disrupting the viral replication cycle. The most effective treatment regimens for genotype 1a hepatitis C often include a combination of these DAAs, which have been shown to achieve high SVR rates with minimal side effects.

**Why Each Wrong Option is Incorrect**
* **Option A:** Ribavirin-based treatment is no longer the standard of care for genotype 1a hepatitis C due to its lower efficacy and higher side effect profile compared to DAAs.
* **Option B:** Interferon-alpha (IFN-α) monotherapy is not effective for genotype 1a hepatitis C and has largely been replaced by DAAs in treatment guidelines.
* **Option C:** Sofosbuvir monotherapy is not sufficient for genotype 1a hepatitis C, as it requires combination therapy with other DAAs to achieve optimal SVR rates.

**Clinical Pearl / High-Yield Fact**
Remember that genotype 1a hepatitis C requires a combination of DAAs for optimal treatment, whereas genotype 1b may be treated with a simpler regimen.

**Correct Answer:** D. Sofosbuvir + Grazoprevir